MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 14, 2017

Primary Completion Date

December 17, 2024

Study Completion Date

December 17, 2024

Conditions

Cancer

Interventions

DRUG

Karonudib

Dose escalation of administration with Karonudib.

Trial Locations (3)

Sahlgrenska University Hospital, Gothenburg

Karolinska University Hospital, Stockholm

Uppsala University Hospital, Uppsala

All Listed Sponsors

lead

Thomas Helleday Foundation

OTHER

NCT03036228 - MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class | Biotech Hunter | Biotech Hunter